芪苈强心胶囊、复方丹参滴丸对AMI患者PCI术后无复流者相关指标的影响比较-中国药房

芪苈强心胶囊、复方丹参滴丸对AMI患者PCI术后无复流者相关指标的影响比较

请在关注微信后，向客服人员索取文件

篇名：	芪苈强心胶囊、复方丹参滴丸对AMI患者PCI术后无复流者相关指标的影响比较
TITLE：
摘要：	目的：比较芪苈强心胶囊、复方丹参滴丸对急性心肌梗死（AMI）患者经皮冠状动脉介入（PCI）术后无复流者相关指标的影响。方法：90例AMI患者PCI术后存在无复流者随机分为复方丹参滴丸组（45例）和芪苈强心胶囊组（45例）。PCI术前两组患者均嚼服1次阿司匹林咀嚼片300 mg，硫酸氢氯吡格雷片300 mg。术后，两组患者均嚼服阿司匹林咀嚼片100 mg，每日1次+辛伐他汀咀嚼片10 mg，每日1次。在此基础上，复方丹参滴丸组患者给予复方丹参滴丸10丸，口服，每日3次；芪苈强心胶囊组患者给予芪苈强心胶囊4粒，口服，每日3次。两组均连用6个月。观察两组患者治疗前后心肌梗死溶栓治疗（TIMI）血流分级、左心室射血分数（LEVF）和β1-肾上腺素能受体抗体（β1-AR）、β2-AR、α1-AR水平，出血及主要心血管事件发生情况，并记录不良反应发生情况。结果：治疗前，两组患者TIMI血流分级、LEVF、β1-AR、β2-AR、α1-AR水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者TIMI血流分级0～2级例数均显著低于同组治疗前，3级例数均显著高于同组治疗前；LEVF水平均显著高于同组治疗前，且芪苈强心胶囊组LEVF水平显著高于复方丹参滴丸组；β1-AR、β2-AR、α1-AR水平均显著低于同组治疗前，差异均有统计学意义（P＜0.05）。两组患者出血发生率、主要心血管事件发生率比较，差异均无统计学意义（P＞0.05）。两组患者治疗期间均未见明显不良反应发生。结论：芪苈强心胶囊在改善AMI患者PCI术后无复流的效果、安全性方面与复方丹参滴丸相当，在改善心功能方面优于复方丹参滴丸。
ABSTRACT：	OBJECTIVE： To compare the effects of Qili qiangxin capsules and Compound danshen drop pills on related indexes of acute myocardial infarction （AMI） patients without reflow after percutaneous coronary intervention （PCI）. METHODS： A total of 90 AMI patients without reflow after PCI were randomly divided into Compound danshen drop pills group （45 cases） and Qili qiangxin capsules group （45 case）. Both groups were given Aspirin chewable tablets 300 mg and Clopidogrel sulfate tablets 300 mg before PCI. After surgery， both groups were given Aspirin chewable tablets 100 mg， once a day+simvastatin chewable tablets 10 mg， once a day. Based on it， Compound danshen drop pills group was given Compound danshen drop pills， 10 pills， 3 times a day. Qili qiangxin capsules group was given Qili qiangxin capsules， 4 capsules， 3 times a day. Both groups were treated for consecutive 6 months. The blood flow classification of TIMI， LEVF， β1-AR， β2-AR， α1-AR， bleeding and the occurrence of major cardiovascular events were observed in 2 groups before and after treatment. The occurrence of ADR was recorded. RESULTS： Bafore treatment，there was no statistical significance in the blood flow classification of TIMI，the levels of β1-AR， β2-AR and α1-AR between 2 groups（P＞0.05）. After treatment， the case number of 0-2 degree blood flow classification of TIMI in 2 groups were significantly lower than before treatment while the case number of 3 degree were significantly higer than before treatment； the levels of β1-AR， β2-AR and α1-AR were significantly lower than before treatment， while LEVF was significantly higher than before treatment； LEVF of Qili qiangxin capsules group was significantly higher than that of Compound danshen drop pills group， with statistical significance （P＜0.05）. There was statistical significance in the incidence of bleeding and major cardiovascular events between 2 groups （P＞0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： Qili qiangxin capsules is similar to Compound danshen drop pills in improving no-reflow efficacy and safety of AMI patients after PCI， but it is better than Compound danshen drop pill in improving cardiac function.
期刊：	2017年第28卷第18期
作者：	于淳，李中言，于东汇，翟桂娟
AUTHORS：	YU Chun，LI Zhongyan，YU Donghui，ZHAI Guijuan
关键字：	芪苈强心胶囊；复方丹参滴丸；急性心肌梗死；经皮冠状动脉介入；无复流；心功能
KEYWORDS：	Qili qiangxin capsules； Compound danshen drop pills； Acute myocardial infraction； Percutaneous coronary intervention；No-reflow； Cardiac function
阅读数：	726 次
本月下载数：	5 次

* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！